Streetbeat News

Products Services

TSLA

The article discusses the 'Elon Musk Premium' for Tesla (TSLA), highlighting that 43% of retail investors own TSLA shares, more than any other company in the S&P 500. The CEO, Elon Musk, is a significant factor in their investment decisions.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

TOL

Toll Brothers has announced the grand opening of the Travisso - Verona Collection in Leander, Texas. This exclusive community offers luxurious single-family homes with access to award-winning amenities in the Texas Hill Country.

Portfolio Pulse from

November 14, 2024 | 10:00 pm

HAS

Hasbro is set to participate in the Morgan Stanley Global Consumer and Retail Conference, which could provide insights into the company's strategies and future outlook.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

TRAW

Traws Pharma, a clinical stage biopharmaceutical company, provided a business update and reported its Q3 2024 financial results. The company focuses on developing oral small molecules for respiratory viral diseases.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

POET

POET Technologies Inc. reported its third quarter 2024 financial results, highlighting its role as a designer and developer of optical interposers and photonic integrated circuits for various markets. The results are available on SEDAR.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

XONI

Xtreme One Entertainment has released its third quarter 2024 financial results, highlighting continued investment in the production and distribution of XFC Live Events as part of its long-term strategic growth plan.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

XGN

Exagen Inc. has completed validation and regulatory submission for new lupus and rheumatoid arthritis biomarkers on its AVISE® CTD platform, enhancing diagnostic clarity for autoimmune diseases.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

PEYE

Precision Optics has received an initial production order for a single-use ophthalmic program, marking the second such program to move into production this year. This development highlights a new growth opportunity for the company.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

INBX

Inhibrx Biosciences reported its third quarter 2024 financial results, highlighting the completion of the sale of INBRX-101 to Sanofi S.A.

Portfolio Pulse from

November 14, 2024 | 9:45 pm

EVFM

Evofem Biosciences reported a 31% improvement in loss from operations for Q3 2024, acquired SOLOSEC, an FDA-approved antibiotic, and secured a commercial agreement for Phexxi in the Middle East.

Portfolio Pulse from

November 14, 2024 | 9:45 pm